Clinical applications of gamma delta T cells with multivalent immunity

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Deniger, Drew C ^a   Moyes, Judy S ^b   Cooper, Laurence J N ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Adoptive T cell therapy; Allogeneic transplantation; Artificial APC; Cancer; Chimeric antigen receptors; Immunotherapy; T cell receptor; T cells

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; BISPHOSPHONIC ACID DERIVATIVE; BROMOHYDRIN PYROPHOSPHATE; GAMMA INTERFERON; INTERLEUKIN 2; MEVALONATE KINASE; OKT 3; PAMIDRONIC ACID; PYROPHOSPHATE; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; BONE CANCER; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DNA MODIFICATION; GAMMA DELTA T LYMPHOCYTE; GASTROINTESTINAL TUMOR; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; MELANOMA; NON SMALL CELL LUNG CANCER; OSTEOPOROSIS; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER;

EID: 84919478412     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00636     Document Type: Review

References (116)

1. Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol (2013) 13(2):88-100. doi:10.1038/nri3384
2. Kabelitz D. Gammadelta T-cells: cross-talk between innate and adaptive immunity. Cell Mol Life Sci (2011) 68(14):2331-3. doi:10.1007/s00018-011-0696-4
3. Hannani D, Ma Y, Yamazaki T, Dechanet-Merville J, Kroemer G, Zitvogel L. Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol (2012) 33(5):199-206. doi:10.1016/j.it.2012.01.006
4. Xiang Z, Liu Y, Zheng J, Liu M, Lv A, Gao Y, et al. Targeted activation of human Vγ9Vδ2-T cells controls Epstein-Barr virus-induced B Cell lymphoproliferative disease. Cancer Cell (2014) 26(4):565-76. doi:10.1016/j.ccr.2014.07.026
5. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol (2009) 27:591-619. doi:10.1146/annurev.immunol.021908.132706
6. Kalyan S, Kabelitz D. Defining the nature of human gammadelta T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol (2013) 10(1):21-9. doi:10.1038/cmi.2012.44
7. Koretzky GA. Multiple roles of CD4 and CD8 in T cell activation. J Immunol (2010) 185(5):2643-4. doi:10.4049/jimmunol.1090076
8. Van Laethem F, Tikhonova AN, Singer A. MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection. Trends Immunol (2012) 33(9):437-41. doi:10.1016/j.it.2012.05.006
9. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol (2002) 2(5):309-22. doi:10.1038/nri798
10. Sato K, Ohtsuka K, Watanabe H, Asakura H, Abo T. Detailed characterization of gamma delta T cells within the organs in mice: classification into three groups. Immunology (1993) 80(3):380-7.
11. Kabelitz D, Kalyan S, Oberg HH, Wesch D. Human Vdelta2 versus non-Vdelta2 gammadelta T cells in antitumor immunity. Oncoimmunology (2013) 2(3):e23304. doi:10.4161/onci.23304
12. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res (2007) 67(1):5-8. doi:10.1158/0008-5472.CAN-06-3069
13. Lefranc MP. Nomenclature of the human T cell receptor genes. Curr Protoc Immunol (2001) Appendix 1:Appendix 1O. doi:10.1002/0471142735.ima01os40
14. Xiong N, Raulet DH. Development and selection of gammadelta T cells. Immunol Rev (2007) 215:15-31. doi:10.1111/j.1600-065X.2006.00478.x
15. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity (2009) 31(2):184-96. doi:10.1016/j.immuni.2009.08.006
16. Hao J, Wu X, Xia S, Li Z, Wen T, Zhao N, et al. Current progress in gammadelta T-cell biology. Cell Mol Immunol (2010) 7(6):409-13. doi:10.1038/cmi.2010.50
17. Ishikawa H, Naito T, Iwanaga T, Takahashi-Iwanaga H, Suematsu M, Hibi T, et al. Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics. Immunol Rev (2007) 215:154-65. doi:10.1111/j.1600-065X.2006.00473.x
18. Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol (2002) 2(5):336-45. doi:10.1038/nri797
19. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol (2010) 10(7):467-78. doi:10.1038/nri2781
20. Chodaczek G, Papanna V, Zal MA, Zal T. Body-barrier surveillance by epidermal gammadelta TCRs. Nat Immunol (2012) 13(3):272-82. doi:10.1038/ni.2240
21. Xu B, Pizarro JC, Holmes MA, McBeth C, Groh V, Spies T, et al. Crystal structure of a gammadelta T-cell receptor specific for the human MHC class I homolog MICA. Proc Natl Acad Sci U S A (2011) 108(6):2414-9. doi:10.1073/pnas.1015433108
22. Li J, Cui L, He W. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA. Cell Mol Immunol (2005) 2(4):253-8.
23. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 285(5428):727-9. doi:10.1126/science.285.5428.727
24. Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, et al. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol (2007) 66(2-3):320-8. doi:10.1111/j.1365-3083.2007.01963.x
25. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS, et al. Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med (2000) 191(6):937-48. doi:10.1084/jem.191.6.937
26. Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, et al. CD1d-lipid antigen recognition by the gammadelta TCR. Nat Immunol (2013) 14(11):1137-45. doi:10.1038/ni.2713
27. Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ. Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity. J Immunol (2012) 188(8):3928-39. doi:10.4049/jimmunol.1103582
28. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Rysselberge M, et al. Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med (2010) 207(4):807-21. doi:10.1084/jem.20090348
29. Wesch D, Hinz T, Kabelitz D. Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. Int Immunol (1998) 10(8):1067-75. doi:10.1093/intimm/10.8.1067
30. Bukowski JF, Morita CT, Brenner MB. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity (1999) 11(1):57-65. doi:10.1016/S1074-7613(00)80081-3
31. Wang L, Kamath A, Das H, Li L, Bukowski JF. Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J Clin Invest (2001) 108(9):1349-57. doi:10.1172/JCI13584
32. Munk ME, Elser C, Kaufmann SH. Human gamma/delta T-cell response to Listeria monocytogenes protein components in vitro. Immunology (1996) 87(2):230-5. doi:10.1046/j.1365-2567.1996.470549.x
33. Green AE, Lissina A, Hutchinson SL, Hewitt RE, Temple B, James D, et al. Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin. Clin Exp Immunol (2004) 136(3):472-82. doi:10.1111/j.1365-2249.2004.02472.x
34. Mookerjee-Basu J, Vantourout P, Martinez LO, Perret B, Collet X, Perigaud C, et al. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol (2010) 184(12):6920-8. doi:10.4049/jimmunol.0904024
35. Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol (2009) 183(6):3848-57. doi:10.4049/jimmunol.0901085
36. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005) 22(1):71-80. doi:10.1016/j.immuni.2004.11.012
37. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science (1994) 264(5156):267-70. doi:10.1126/science.8146660
38. Farnault L, Gertner-Dardenne J, Gondois-Rey F, Michel G, Chambost H, Hirsch I, et al. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation. Bone Marrow Transplant (2013) 48(11):1478-9. doi:10.1038/bmt.2013.75
39. Hacker G, Kromer S, Falk M, Heeg K, Wagner H, Pfeffer K. V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes. J Immunol (1992) 149(12):3984-9.
40. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, et al. The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood (2010) 116(12):2164-72. doi:10.1182/blood-2010-01-255166
41. Kabelitz D, Hinz T, Dobmeyer T, Mentzel U, Marx S, Bohme A, et al. Clonal expansion of Vgamma3/Vdelta3-expressing gammadelta T cells in an HIV-1/2-negative patient with CD4 T-cell deficiency. Br J Haematol (1997) 96(2):266-71. doi:10.1046/j.1365-2141.1997.d01-2027.x
42. Thompson K, Roelofs AJ, Jauhiainen M, Monkkonen H, Monkkonen J, Rogers MJ. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol (2010) 658:11-20. doi:10.1007/978-1-4419-1050-9_2
43. Nagamine I, Yamaguchi Y, Ohara M, Ikeda T, Okada M. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Hiroshima J Med Sci (2009) 58(1):37-44.
44. Chiplunkar S, Dhar S, Wesch D, Kabelitz D. gammadelta T cells in cancer immunotherapy: current status and future prospects. Immunotherapy (2009) 1(4):663-78. doi:10.2217/imt.09.27
45. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 184(6):3260-8. doi:10.4049/jimmunol.0903454
46. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol (2009) 182(6):3423-31. doi:10.4049/jimmunol.0803068
47. Chargui J, Combaret V, Scaglione V, Iacono I, Peri V, Valteau-Couanet D, et al. Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother (2010) 33(6):591-8. doi:10.1097/CJI.0b013e3181dda207
48. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem (2001) 276(21):18337-44. doi:10.1074/jbc.M100495200
49. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. gammadelta T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology (2014) 3(1):e27572. doi:10.4161/onci.27572
50. Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res (2010) 70(24):10024-7. doi:10.1158/0008-5472.CAN-10-3236
51. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102(1):200-6. doi:10.1182/blood-2002-12-3665
52. Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, et al. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial. J Immunother (2012) 35(2):205-13. doi:10.1097/CJI.0b013e318245bb1e
53. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother (2011) 60(10):1447-60. doi:10.1007/s00262-011-1049-8
54. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 67(15):7450-7. doi:10.1158/0008-5472.CAN-07-0199
55. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 161(2):290-7. doi:10.1111/j.1365-2249.2010.04167.x
56. Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS (2009) 23(5):555-65. doi:10.1097/QAD.0b013e3283244619
57. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother (2007) 56(4):469-76. doi:10.1007/s00262-006-0199-6
58. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2008) 57(11):1599-609. doi:10.1007/s00262-008-0491-8
59. Bennouna J, Levy V, Sicard H, Senellart H, Audrain M, Hiret S, et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors. Cancer Immunol Immunother (2010) 59(10):1521-30. doi:10.1007/s00262-010-0879-0
60. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg (2010) 37(5):1191-7. doi:10.1016/j.ejcts.2009.11.051
61. Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother (2011) 34(2):202-11. doi:10.1097/CJI.0b013e318207ecfb
62. Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, et al. Ex vivo characterization of gammadelta T-cell repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the interleukin-2 receptor beta-chain and the common gamma-chain. Cytotherapy (2013) 15(4):481-91. doi:10.1016/j.jcyt.2012.12.004
63. Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol (2009) 37(8):956-68. doi:10.1016/j.exphem.2009.04.008
64. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother (2011) 60(8):1075-84. doi:10.1007/s00262-011-1021-7
65. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer (2011) 105(6):778-86. doi:10.1038/bjc.2011.293
66. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant (2007) 39(12):751-7. doi:10.1038/sj.bmt.1705650
67. Lamb LS Jr, Gee AP, Hazlett LJ, Musk P, Parrish RS, O'Hanlon TP, et al. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy (1999) 1(1):7-19. doi:10.1080/0032472031000141295
68. Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother (1996) 5(5):503-9. doi:10.1089/scd.1.1996.5.503
69. Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant (2001) 27(6):601-6. doi:10.1038/sj.bmt.1702830
70. Scheper W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S, et al. gammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia (2013) 27(6):1328-38. doi:10.1038/leu.2012.374
71. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells. J Transl Med (2014) 12:45. doi:10.1186/1479-5876-12-45
72. Qi J, Zhang J, Zhang S, Cui L, He W. Immobilized MICA could expand human Vdelta1 gammadelta T cells in vitro that displayed major histocompatibility complex class I chain-related A-dependent cytotoxicity to human epithelial carcinomas. Scand J Immunol (2003) 58(2):211-20. doi:10.1046/j.1365-3083.2003.01288.x
73. Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y, et al. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther (2009) 8(16):1540-9. doi:10.4161/cbt.8.16.8950
74. Zhou J, Kang N, Cui L, Ba D, He W. Anti-gammadelta TCR antibody-expanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol (2012) 9(1):34-44. doi:10.1038/cmi.2011.16
75. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett (2010) 297(1):126-36. doi:10.1016/j.canlet.2010.05.005
76. Lopez RD, Xu S, Guo B, Negrin RS, Waller EK. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood (2000) 96(12):3827-37.
77. Deniger DC, Maiti S, Mi T, Switzer K, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res (2014) 20(22):5708-19. doi:10.1158/1078-0432.CCR-13-3451
78. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther (2013) 21(3):638-47. doi:10.1038/mt.2012.267
79. Fisher J, Yan M, Heuijerjans J, Carter L, Abolhassani A, Frosch J, et al. Neuroblastoma killing properties of V-d 2 and V-d2 negative gamma delta T cells following expansion by artificial antigen presenting cells. Clin Cancer Res (2014) 20(22):5720-32. doi:10.1158/1078-0432.CCR-13-3464
80. Dechanet-Merville J. Promising cell-based immunotherapy using gamma delta T cells: together is better. Clin Cancer Res (2014) 20(22):5573-5. doi:10.1158/1078-0432.CCR-14-1371
81. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep (2012) 2:249. doi:10.1038/srep00249
82. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS One (2013) 8(5):e64138. doi:10.1371/journal.pone.0064138
83. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, et al. Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp (2013) 72:e50070. doi:10.3791/50070
84. Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S, et al. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother (2014) 37(4):204-13. doi:10.1097/CJI.0000000000000032
85. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood (2011) 118(1):129-38. doi:10.1182/blood-2011-01-331298
86. DeBarros A, Chaves-Ferreira M, d'Orey F, Ribot JC, Silva-Santos B. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human gammadelta peripheral blood lymphocytes. Eur J Immunol (2011) 41(1):195-201. doi:10.1002/eji.201040905
87. Ribot JC, de Barros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, et al. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat Immunol (2009) 10(4):427-36. doi:10.1038/ni.1717
88. Heemskerk MH. T-cell receptor gene transfer for the treatment of leukemia and other tumors. Haematologica (2010) 95(1):15-9. doi:10.3324/haematol.2009.016022
89. van der Veken LT, Coccoris M, Swart E, Falkenburg JH, Schumacher TN, Heemskerk MH. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol (2009) 182(1):164-70. doi:10.4049/jimmunol.182.1.164
90. Hiasa A, Nishikawa H, Hirayama M, Kitano S, Okamoto S, Chono H, et al. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther (2009) 16(5):620-8. doi:10.1038/gt.2009.6
91. Murayama M, Tanaka Y, Yagi J, Uchiyama T, Ogawa K. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas. Anticancer Res (2008) 28(5B):2921-31.
92. van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res (2006) 66(6):3331-7. doi:10.1158/0008-5472.CAN-05-4190
93. Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive gammadeltaT-cell receptor. Blood (2011) 118(1):50-9. doi:10.1182/blood-2010-12-325993
94. Lamb LS Jr, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, et al. Engineered drug resistant gammadelta T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One (2013) 8(1):e51805. doi:10.1371/journal.pone.0051805
95. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest (2007) 117(5):1204-12. doi:10.1172/JCI32446
96. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using sleeping beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev (2014) 257(1):181-90. doi:10.1111/imr.12137
97. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 116(7):1035-44. doi:10.1182/blood-2010-01-043737
98. Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human gammadelta T cells as mediators of chimeric-receptor redirected anti-tumour immunity. Br J Haematol (2004) 126(4):583-92. doi:10.1111/j.1365-2141.2004.05077.x
99. Hackett PB Jr, Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ, et al. Efficacy and safety of sleeping beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther (2011) 11(5):341-9. doi:10.2174/156652311797415827
100. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther (2010) 18(4):674-83. doi:10.1038/mt.2010.2
101. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res (2013) 161(4):265-83. doi:10.1016/j.trsl.2012.12.005
102. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother (2013) 36(2):112-23. doi:10.1097/CJI.0b013e3182811ce9
103. Wadman SA, Clark KJ, Hackett PB. Fishing for answers with transposons. Mar Biotechnol (NY) (2005) 7(3):135-41. doi:10.1007/s10126-004-0068-2
104. Liu G, Aronovich EL, Cui Z, Whitley CB, Hackett PB. Excision of sleeping beauty transposons: parameters and applications to gene therapy. J Gene Med (2004) 6(5):574-83. doi:10.1002/jgm.486
105. Liu G, Geurts AM, Yae K, Srinivasan AR, Fahrenkrug SC, Largaespada DA, et al. Target-site preferences of sleeping beauty transposons. J Mol Biol (2005) 346(1):161-73. doi:10.1016/j.jmb.2004.09.086
106. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res (2008) 68(8):2961-71. doi:10.1158/0008-5472.CAN-07-5600
107. Tran E, Rosenberg SA. T-cell therapy against cancer mutations. Oncotarget (2014) 5(13):4579-80.
108. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 344(6184):641-5. doi:10.1126/science.1251102
109. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19(6):747-52. doi:10.1038/nm.3161
110. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity (2007) 27(2):334-48. doi:10.1016/j.immuni.2007.05.020
111. Raspollini MR, Castiglione F, Rossi Degl'innocenti D, Amunni G, Villanucci A, Garbini F, et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol (2005) 16(4):590-6. doi:10.1093/annonc/mdi112
112. Forget MA, Malu S, Liu H, Toth C, Maiti S, Kale C, et al. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother (2014) 37(9):448-60. doi:10.1097/CJI.0000000000000056
113. Anderson J, Gustafsson K, Himoudi N. Licensing of killer dendritic cells in mouse and humans: functional similarities between IKDC and human blood gammadelta T-lymphocytes. J Immunotoxicol (2012) 9(3):259-66. doi:10.3109/1547691X.2012.685528
114. Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, et al. Human gammadelta T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol (2012) 188(4):1708-16. doi:10.4049/jimmunol.1102654
115. Anderson J, Gustafsson K, Himoudi N, Yan M, Heuijerjans J. Licensing of gammadeltaT cells for professional antigen presentation: a new role for antibodies in regulation of antitumor immune responses. Oncoimmunology (2012) 1(9):1652-4. doi:10.4161/onci.21971
116. Kang N, Tang L, Li X, Wu D, Li W, Chen X, et al. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human. Immunol Lett (2009) 125(2):105-13. doi:10.1016/j.imlet.2009.06.005